Market Cap 25.34M
Revenue (ttm) 3.55M
Net Income (ttm) -12.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -342.54%
Debt to Equity Ratio 0.07
Volume 33,800
Avg Vol 65,640
Day's Range N/A - N/A
Shares Out 16.67M
Stochastic %K 69%
Beta 1.50
Analysts Strong Sell
Price Target $7.87

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 400 6400
Address:
2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, United States
Steadynwise
Steadynwise Aug. 25 at 2:14 PM
1 · Reply
MQuick
MQuick Aug. 25 at 12:50 PM
0 · Reply
itsMeRich
itsMeRich Aug. 24 at 1:45 PM
$MRKR Good morning my little POS
0 · Reply
MrDint
MrDint Aug. 22 at 4:19 PM
$MRKR ...because H.C.Wainwright is leading the next dilution as the last one. They always pump it before they dump shares. Don't be a sheep.
1 · Reply
contrast82
contrast82 Aug. 22 at 10:29 AM
$MRKR H.C. Wainwright officially reaffirmed its Buy rating for Marker Therapeutics on Friday and is sticking to an extremely aggressive price target of $10.00. This occurred immediately following an exclusive discussion with Marker’s CEO, Juan Vera, at the Annual Cell Therapy Virtual Conference...."
0 · Reply
contrast82
contrast82 Aug. 22 at 10:25 AM
$MRKR "Pivotal-Start-Guarantee in the Q2 report: In the recently published quarterly report (10-Q), management officially maintained the wording that the crucial clinical registrational trials will start as planned. This shows investors that the funds (the company has cash until the end of 2026) are sufficient to reach these milestones without immediate, dilutive capital raises...." Wait for Monday dip 1,22- 1,25.🧨🗼
0 · Reply
dwaslimit1
dwaslimit1 Aug. 21 at 5:06 PM
$MRKR you mean it took Moderna issuing a press release on the promise of vaccines in cancer trials to realize that Marker should be worth 100 times where it's at today? Get in on the ground floor! They have a decade of data to back up their efficacy.
1 · Reply
TerribleExample563
TerribleExample563 Aug. 19 at 7:36 PM
$MRKR what is going on here? Never seen this move
1 · Reply
dwaslimit1
dwaslimit1 Aug. 19 at 5:00 PM
$MRKR their product is superior to Moderna considering it doesn't have to be personalized. It's much more versatile. They've also had compelling efficacy without being a conjunction therapy which is also why it is superior to Moderna. I don't see why this can't go to 100 million.
0 · Reply
MrDint
MrDint Aug. 19 at 3:06 PM
$MRKR are they making love again? Did Vera whisper to HC Wainwright that its coming so they running it up? u really can't put anything pass these fckers
0 · Reply
Latest News on MRKR
Marker Therapeutics Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 12 days ago

Marker Therapeutics Quarterly report: Q2 2026


Marker Therapeutics Quarterly report: Q1 2026

May 18, 2026, 2:00 AM EDT - 3 months ago

Marker Therapeutics Quarterly report: Q1 2026


Marker Therapeutics Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Marker Therapeutics Proxy statement: Proxy filing


Marker Therapeutics Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Marker Therapeutics Proxy statement: Proxy filing


Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)

2026-03-18T21:35:16.000Z - 5 months ago

Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)


Marker Therapeutics Earnings release: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 5 months ago

Marker Therapeutics Earnings release: Q4 2025


Marker Therapeutics Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 5 months ago

Marker Therapeutics Annual report: Q4 2025


Marker Therapeutics Proxy statement: Proxy Filing

Mar 10, 2026, 8:00 AM EDT - 6 months ago

Marker Therapeutics Proxy statement: Proxy Filing


Marker Therapeutics initiated with a Buy at H.C. Wainwright

2025-12-08T13:30:08.000Z - 9 months ago

Marker Therapeutics initiated with a Buy at H.C. Wainwright


Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year

2025-11-14T12:05:51.000Z - 10 months ago

Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year


Marker Therapeutics Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 10 months ago

Marker Therapeutics Earnings release: Q3 2025


Marker Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 10 months ago

Marker Therapeutics Quarterly report: Q3 2025


Marker Therapeutics appoints Penkus Corzo to board of directors

2025-11-05T12:50:27.000Z - 10 months ago

Marker Therapeutics appoints Penkus Corzo to board of directors


Marker Therapeutics Transcript: Study Update

Aug 26, 2025, 8:30 AM EDT - 1 year ago

Marker Therapeutics Transcript: Study Update


Marker Therapeutics Press release: Study Update

Aug 26, 2025, 8:30 AM EDT - 1 year ago

Marker Therapeutics Press release: Study Update


Marker Therapeutics Slides: Corporate Presentation

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics Slides: Corporate Presentation


Marker Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Quarterly report: Q2 2025


Marker Therapeutics Slides: Corporate Presentation

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Slides: Corporate Presentation


Marker Therapeutics Slides: Investor Presentation

May 20, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Slides: Investor Presentation


Marker Therapeutics Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

Marker Therapeutics Quarterly report: Q1 2025


Marker Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing


Marker Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing


Marker Therapeutics Annual report: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Annual report: Q4 2024


Marker Therapeutics Earnings release: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Earnings release: Q4 2024


Marker Therapeutics initiated with a Buy at Canaccord

2025-03-05T11:32:28.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Canaccord


Marker Therapeutics initiated with a Buy at Canaccord

2025-03-05T10:17:01.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Canaccord


Marker Therapeutics initiated with a Buy at Brookline

2025-02-10T23:05:05.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Brookline


Marker Therapeutics Proxy statement: Proxy Filing

Feb 4, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing


Marker Therapeutics Proxy statement: Proxy Filing

Feb 4, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing


Marker Therapeutics Proxy statement: Proxy Filing

Jan 13, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing


Marker Therapeutics provides update on MT-601 patients

2024-12-19T13:10:51.000Z - 1 year ago

Marker Therapeutics provides update on MT-601 patients


Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:06 AM EST - 1 year ago

Marker Therapeutics Announces $16.1 Million Private Placement


Marker Therapeutics Slides: Corporate Presentation

Dec 19, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Slides: Corporate Presentation


Marker Therapeutics awarded $9.5M grant from CPRIT

2024-12-17T12:05:36.000Z - 1 year ago

Marker Therapeutics awarded $9.5M grant from CPRIT


Marker Therapeutics files $300M mixed securities shelf

2024-11-27T21:30:12.000Z - 1 year ago

Marker Therapeutics files $300M mixed securities shelf


Marker Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Quarterly report: Q3 2024


Marker Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Earnings release: Q3 2024


Marker Therapeutics Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Quarterly report: Q2 2024


Marker Therapeutics Earnings release: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Earnings release: Q2 2024


Marker Therapeutics Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Quarterly report: Q1 2024


Marker Therapeutics Earnings release: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Earnings release: Q1 2024


Marker Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Marker Therapeutics Proxy statement: Proxy Filing


Marker Therapeutics Annual report: Q4 2023

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Marker Therapeutics Annual report: Q4 2023


Marker Therapeutics Earnings release: Q4 2023

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Marker Therapeutics Earnings release: Q4 2023


Marker Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 3 years ago

Marker Therapeutics Quarterly report: Q3 2023


Marker Therapeutics Earnings release: Q3 2023

Nov 9, 2023, 7:00 AM EST - 3 years ago

Marker Therapeutics Earnings release: Q3 2023


Marker Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Quarterly report: Q2 2023


Marker Therapeutics Earnings release: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Earnings release: Q2 2023


Marker Therapeutics Transcript: Status Update

Aug 9, 2023, 11:00 AM EDT - 3 years ago

Marker Therapeutics Transcript: Status Update


Marker Therapeutics Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Marker Therapeutics Proxy statement: Proxy Filing


Marker Therapeutics Annual report: Q4 2022

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Marker Therapeutics Annual report: Q4 2022


Marker Therapeutics Earnings release: Q4 2022

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Marker Therapeutics Earnings release: Q4 2022


Marker Therapeutics Registration statement: Registration Filing

Dec 23, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics Registration statement: Registration Filing


Marker Therapeutics Quarterly report: Q3 2022

Nov 10, 2022, 7:00 AM EST - 4 years ago

Marker Therapeutics Quarterly report: Q3 2022


Marker Therapeutics Earnings release: Q3 2022

Nov 10, 2022, 7:00 AM EST - 4 years ago

Marker Therapeutics Earnings release: Q3 2022


Marker Therapeutics Quarterly report: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Quarterly report: Q2 2022


Marker Therapeutics Earnings release: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Earnings release: Q2 2022


Marker Therapeutics Quarterly report: Q1 2022

May 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Quarterly report: Q1 2022


Marker Therapeutics Earnings release: Q1 2022

May 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Earnings release: Q1 2022


Steadynwise
Steadynwise Aug. 25 at 2:14 PM
1 · Reply
MQuick
MQuick Aug. 25 at 12:50 PM
0 · Reply
itsMeRich
itsMeRich Aug. 24 at 1:45 PM
$MRKR Good morning my little POS
0 · Reply
MrDint
MrDint Aug. 22 at 4:19 PM
$MRKR ...because H.C.Wainwright is leading the next dilution as the last one. They always pump it before they dump shares. Don't be a sheep.
1 · Reply
contrast82
contrast82 Aug. 22 at 10:29 AM
$MRKR H.C. Wainwright officially reaffirmed its Buy rating for Marker Therapeutics on Friday and is sticking to an extremely aggressive price target of $10.00. This occurred immediately following an exclusive discussion with Marker’s CEO, Juan Vera, at the Annual Cell Therapy Virtual Conference...."
0 · Reply
contrast82
contrast82 Aug. 22 at 10:25 AM
$MRKR "Pivotal-Start-Guarantee in the Q2 report: In the recently published quarterly report (10-Q), management officially maintained the wording that the crucial clinical registrational trials will start as planned. This shows investors that the funds (the company has cash until the end of 2026) are sufficient to reach these milestones without immediate, dilutive capital raises...." Wait for Monday dip 1,22- 1,25.🧨🗼
0 · Reply
dwaslimit1
dwaslimit1 Aug. 21 at 5:06 PM
$MRKR you mean it took Moderna issuing a press release on the promise of vaccines in cancer trials to realize that Marker should be worth 100 times where it's at today? Get in on the ground floor! They have a decade of data to back up their efficacy.
1 · Reply
TerribleExample563
TerribleExample563 Aug. 19 at 7:36 PM
$MRKR what is going on here? Never seen this move
1 · Reply
dwaslimit1
dwaslimit1 Aug. 19 at 5:00 PM
$MRKR their product is superior to Moderna considering it doesn't have to be personalized. It's much more versatile. They've also had compelling efficacy without being a conjunction therapy which is also why it is superior to Moderna. I don't see why this can't go to 100 million.
0 · Reply
MrDint
MrDint Aug. 19 at 3:06 PM
$MRKR are they making love again? Did Vera whisper to HC Wainwright that its coming so they running it up? u really can't put anything pass these fckers
0 · Reply
itsMeRich
itsMeRich Aug. 19 at 3:03 PM
$MRKR moving up with the rest of the vaccine stocks…… doubt it lasts
1 · Reply
GoIrish1776
GoIrish1776 Aug. 19 at 12:08 PM
Personalized cancer vaccine from Moderna, Merck shows promise in late-stage trial $MRKR https://www.cnbc.com/2026/08/19/moderna-merck-cancer-vaccine-shows-initial-late-stage-melanoma-data.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
2 · Reply
MrDint
MrDint Aug. 18 at 1:17 PM
$MRKR they received 4 million from Department of War in July and did not issue a press release!?!? Yet the stock climb to 1.70s in July. So retailers are left in the dark but the insiders and Wall Street are making love. What a terrible company.
0 · Reply
itsMeRich
itsMeRich Aug. 16 at 1:18 PM
$MRKR Marker’s management absolutely sucks! No updates to their shareholders on their trials-no press releases- absolutely ridiculous! Why would anyone invest in this company?
0 · Reply
JohnStuartMill
JohnStuartMill Aug. 15 at 6:32 AM
$MRKR Management noted existing cash resources project runway only into the second quarter of 2027, "creating substantial doubt about the company’s ability to continue as a going concern without additional funding." "We have no sources of income, other than grant income, to provide incoming cash flows to sustain our future operations" GREAT, I'd much rather hear ... "creating substantial doubt about the company’s ability to continue as a going concern", than updates on Lymphoma or new patients or Pancreatic.
0 · Reply
Trak2
Trak2 Aug. 14 at 11:16 PM
$MRKR 10-q is out
0 · Reply
MrDint
MrDint Aug. 12 at 7:27 PM
$MRKR Fake bump. Being done in anticipation of earnings report. Current projected cash on hand is somewhere around 12 million and with no new data, post earnings report it will slide to 80 cents. Only a meaningful pr can change that trajectory but Vera is not your guy. He is a prop not a real CEO
0 · Reply
MrDint
MrDint Aug. 11 at 4:20 PM
$MRKR chart is showing 80 cents again. every move upwards has being rejected so far: couldn't break 1.80 on the run up some weeks back, and couldnt break 1.35 after the collapse to 1.05 All signs point further south.
0 · Reply
MrDint
MrDint Aug. 7 at 7:35 PM
$MRKR offering... whispering is they short on cash and intend to do a raise. chart shows 50 cents is possible with a bottom of .22 cents. historic lows. how Vera still has his job?
0 · Reply
tradingviewcyp
tradingviewcyp Aug. 5 at 7:36 PM
$MRKR Somebody is playing with this stock by using their $70K capital. Up down up down. And Dr. Vera doesn’t care. His company is in stock market, when he needs money, he announces same news to the media to get money from fools. This is the game. Everybody can use his company for getting easy money from customers, he doesn’t care. You can check this on buy/sells.
0 · Reply
tradingviewcyp
tradingviewcyp Aug. 5 at 3:52 PM
$MRKR Hehehehe way to below 1$. ✌️
0 · Reply
MrDint
MrDint Aug. 3 at 6:54 PM
$MRKR is the move up based upon a retailer emailing the company the response is a promise of robust data soon? how soon and how robust? Vera is not the guy to bet on. Truckloads of promises only.
0 · Reply